Thus far, several different transcript types in AML with t(8;16) have been identified by reverse transcription (RT)–PCR. However, the question of the relevant leukemogenic fusion is still under debate ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

As someone with acute myeloid leukemia (AML), the best choice you can make is to receive care at an academic medical center, like Fred Hutch Cancer Center, from physicians who specialize in AML.

A bone marrow or stem cell transplant may be beneficial for people with intermediate- to high-risk acute myeloid leukemia (AML) who are in remission and can tolerate an intensive treatment plan. Acute ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. It affects the ability of your bone marrow to produce normal-functioning white blood cells (WBCs). The risk of this type of ...

As consolidation therapy for acute myeloid leukemia (AML), allogeneic hematopoietic stem-cell transplantation provides a benefit in part by means of an immune-mediated graft-versus-leukemia effect. We ...

Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies Current data highlight the potential role for immunotherapy in AML. Gaps in knowledge include limited studies on ...